By shifting to higher margin produce and increasing sales of cut herbs through an expanded distribution network, Edible ...

Cardiff has a cash runway of 5-6 quarters, but will need additional funding, potentially leading to significant shareholder ...

Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, ...

A new case report was published in Oncotarget's Volume 15 on October 11, 2024, entitled "A case of adenosquamous pancreatic ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit attended the 5th RAS Initiative Symposium, hearing about ...

Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the trea ...

Recent Highlights In November 2024, Elicio presented a poster, “AMPLIFY-7P Phase 1a: Lymph node-targeted amphiphile therapeutic cancer vaccine in patients with high relapse risk KRAS mutated ...

Batsmen have forgotten to play with soft hands because in T20 cricket they are used to muscling the ball, says head coach ...

If approved, Verastem expects that avutometinib plus defactinib will be the first-ever FDA-approved treatment specifically for adult patients in the United States with recurrent KRAS mutant LGSOC.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the ...

“ALTA3263 induces deep and durable tumor regressions in preclinical models addicted to the most common KRAS mutations, G12D, G12V, and G12C,” said Eric Murphy, Ph.D., co-founder and CEO of ...

Verastem Oncology submits NDA to US FDA for avutometinib plus defactinib to treat recurrent KRAS mutant low-grade serous ovarian cancer: Boston Monday, November 4, 2024, 14:00 Hrs ...